Proprietary Technology

We continue to investigate the use of our proprietary extended-release drug delivery technology platform to meet various unmet medical needs. Our FDA approved products and future product candidates include the following attributes and administration features:

  • An extended-release profile, providing the convenience of once-daily dosing
  • Designed with patients in mind
    • ODT that disintegrates in the mouth without water
    • Liquid suspension
  • Taste-masking of bitter medications, with flavoring options
  • Convenient single-unit blister packaging, which is portable and discreet

Our Proprietary Technology Platform

We are able to apply the XR-ODT and XR oral suspension technologies to other active pharmaceutical ingredients, or APIs. We have the ability to produce drug-loaded micro-particles with complex release profiles, which allows us to develop ODT or oral suspension formulations that can mimic various release profiles not otherwise available in XR-ODT or XR oral suspension form.

Rapidly Disintegrating Ionic Masking – XR ODT

Our Rapidly Disintegrating Ionic Masking, or RDIM, technology utilizes an oral-disintegrating, extended-release, taste-masked pharmaceutical composition that can withstand compression forces associated with standard tableting technology, allowing for a drug to be incorporated into the ODT dosage form using ion resin technology. This technology not only provides extended-release and controlled-release properties, it is designed to mask the taste of the active drug.

Dynamic Time Release Suspension® – XR Oral Suspension

Our Dynamic Time Release Suspension®, or DTRS®, technology encompasses a set of process technologies and know-how to manufacture and test extended-release oral suspension products that are shelf-stable. Our DTRS® technology not only provides for an extended-release, ready-to-use oral suspension but may offer taste-masking of the active pharmaceutical ingredient.

Kinetically Controlled Tamper Protection – XR ODT and XR Oral Suspension

Our Kinetically Controlled Tamper Protection, or KCTP, technology is designed to prevent abuse by altering the kinetics of the drug product and can be used in conjunction with both our XR-ODT and XR oral suspension dosage forms. We believe that our KCTP technology can be applied to opioid-based pain products or other DEA scheduled drug products for which abuse and dose dumping are known problems.